Medicine and Dentistry
Systematic Review
100%
Giant-Cell Arteritis
66%
Optical Coherence Tomography
66%
Vasculotropin
63%
Wet Macular Degeneration
53%
Meta-Analysis
52%
Oximetry
47%
Ophthalmology
42%
Oxygen Saturation
40%
Systematic Review with Meta-Analysis
40%
Aflibercept
40%
Central Serous Retinopathy
40%
Vessel Diameter
35%
Dark Adaptation
32%
Eye Disease
31%
Observational Study
30%
Retinal Blood Vessel
29%
Insulin Pump
26%
Hyperglycemia
26%
Faricimab
26%
Randomized Controlled Trial
26%
Diabetic Retinopathy
25%
Fluorodeoxyglucose F 18
24%
Positron Emission Tomography-Computed Tomography
23%
Choroid
23%
Temporal Artery
21%
Arteritic Anterior Ischemic Optic Neuropathy
20%
Hemoglobin A1c
18%
Artery
16%
Comorbidity
16%
Retinopathy
16%
Maculopathy
16%
Insulin Dependent Diabetes Mellitus
16%
Multiple Choice Test
15%
Retina Blood Flow
15%
Patient with Type 2 Diabetes
15%
Fluorescein Angiography
15%
Capillary
13%
All Cause Mortality
13%
Adverse Event
13%
Vertebral Artery
13%
Vasculitis
13%
Proliferative Diabetic Retinopathy
13%
Electroretinography
13%
Conjunctiva Tumor
13%
COVID-19
13%
Insulin Infusion
13%
Endophthalmitis
13%
Cardiovascular Risk
13%
Body Mass Index
13%
Keyphrases
Giant Cell Arteritis
66%
Optical Coherence Tomography
49%
Systematic Meta-analysis
40%
Central Serous Chorioretinopathy
40%
Neovascular Age-related Macular Degeneration (nAMD)
40%
Retinal Oximetry
36%
Macular Perfusion
32%
Oxygen Saturation
32%
Dark Adaptation
32%
Anti-VEGF Therapy
28%
Meta-analysis
28%
Insulin Pump Therapy
26%
Acute Hyperglycemia
26%
Peripapillary
26%
Aflibercept
26%
Faricimab
26%
Short-term Outcomes
26%
Intravitreal anti-VEGF
26%
All-cause Mortality
26%
Literature Database
26%
Choroidal Thickness
22%
Retinal Vessel Diameter
22%
18F-FDG PET-CT
22%
Hemoglobin A1c (HbA1c)
18%
Perfusion
18%
Treatment Outcome
18%
Plasma Glucose
17%
Adult Patients
17%
Anterior Ischemic Optic Neuropathy
17%
Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
17%
Treatment Switch
16%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
16%
Diabetes
16%
Randomized Controlled Trial
16%
Retinopathy
16%
Cardiovascular Risk
16%
Retinal Function
16%
Type 1 Diabetes Mellitus (T1DM)
16%
Same-day
16%
Retinal Vascular Network
16%
Retinal Blood Flow
15%
Non-invasive Imaging
15%
High-resolution
15%
Cardiovascular Disease
15%
Ocular Manifestations
15%
Fluorescein Angiography
15%
Blood Oximetry
13%
Retinal Hemodynamics
13%
Vessel Diameter Measurement
13%
Baseline-free
13%
